课题基金 / 基金详情

项目摘要

项目成果

YING-XIAN PAN的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Opiates remain among the most useful and important class of drugs in medicine, but not without problems. This submission proposes to examine two clinically relevant issues in opioid use – safety and tolerance. Most opioids used clinically act through the mu opioid receptor. The mu opioid receptor gene Oprm1 undergoes alternative splicing to generate a family of opioid receptors that can be categorized into three classes based upon their structure, each of which contain a number of variants. Knockout mouse models that selectively remove different sets of Oprm1 variants suggest that morphine acts through only one of these sets of variants while drugs acting through different sets of mu receptors lack respiratory depression, physical dependence and reward while maintaining their analgesic activity, thus enhancing their safety. The focus of this application is to understand the role and significance of the sets of mu opioid receptor splice variants in opioid analgesia, side-effects and tolerance. The current application will explore this concept by generating a mouse model in which selected opioid receptor splice variants can be expressed under native control of the Oprm1 gene, thereby permitting the exploration of their actions in vivo. The second aspect of this application involves tolerance. Preclinicla models reveal that short-term opioid administration leads to progressive tolerance. Yet, cancer patients can be maintained on fixed opioid doses without dose escalation to relieve their pain for many months. In a recent study using an extended chronic administration paradigm we reconciled these observations, showing a progressively increasing tolerance to morphine for up to three weeks that then stabilized with no further increases for as long as 6 weeks. Furthermore, this stabilization was associated with changes of select Oprm1 splice variants in specific brain regions of as much as 400-fold. The second component of this application will explore the stabilization of opioid tolerance with extended administration and potential mechanisms.
期刊论文(146)
专著(0)
科研奖励(0)
会议论文
DOI: --
发表时间: 1997-04
期刊: The Journal of pharmacology and experimental therapeutics
影响因子: --
作者: [G. Rossi;L. Leventhal;Ying Pan;J. L. Cole;W. Su;R. J. Bodnar;G. Pasternak]
通讯作者: G. Rossi;L. Leventhal;Ying Pan;J. L. Cole;W. Su;R. J. Bodnar;G. Pasternak
DOI: 10.1016/0024-3205(94)00753-5
发表时间: 1994
期刊: Life sciences
影响因子: 6.1
作者: [Y. Kolesnikov;Maria-Luisa Maccechini;G. Pasternak;G. Pasternak]
通讯作者: Y. Kolesnikov;Maria-Luisa Maccechini;G. Pasternak;G. Pasternak
DOI: 10.1016/s0165-6147(03)00066-x
发表时间: 2003-04
期刊: Trends in pharmacological sciences
影响因子: 13.8
作者: [S. Snyder;G. Pasternak]
通讯作者: S. Snyder;G. Pasternak
Potency ratios of morphine and morphine-6beta-glucuronide analgesia elicited from the periaqueductal gray, locus coeruleus or rostral ventromedial medulla of rats.
吗啡和吗啡-6β-葡萄糖醛酸从大鼠导水管周围灰质、蓝斑或头端腹内侧延髓引起的镇痛效价比。
DOI: 10.1016/s0006-8993(98)00520-4
发表时间: 1998
期刊: Brain research
影响因子: 2.9
作者: [Krzanowska,EK, Rossi,GC, Pasternak,GW, Bodnar,RJ]
通讯作者: Bodnar,RJ
73
    Pharmacology of opioid actions in vivo
    • 批准号:
      10304208
    • 项目类别:
    • 资助金额:
      $36.09万
    • 财政年份:
      2020
    • 负责人:
      YING-XIAN PAN
    • 依托单位:
    Pharmacology of opioid actions in vivo
    • 批准号:
      10258294
    • 项目类别:
    • 资助金额:
      $33.05万
    • 财政年份:
      2020
    • 负责人:
      YING-XIAN PAN
    • 依托单位:
    Arylepoxamides: A new class of potent, safer analgesics
    海外基金